Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ ... investments on its balance sheet (the entire market cap ...

With no debt and significant cash boosts from equity raises in 2020 and covid vaccine sales in 2021 and 2022, we have no concerns regarding Moderna's balance sheet. The mRNA treatment landscape is ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE, MA / ACCESS ...

To that end, HHS has granted Moderna $590 million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the Massachusetts-based pharmaceutical firm about 72 ...

The maker of vaccines, including the mRNA vaccine for ... Compared to revenue of $5 billion and $9 billion in cash on the balance sheet, Moderna is an interesting opportunity for a turnaround ...